Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Pharmacol Ther. 2007 Feb;81(2):259-64.

GARDASIL: prophylactic human papillomavirus vaccine development--from bench top to bed-side.

Author information

1
Merck Research Laboratories, West Point, Pennsylvania, USA. Li_Shi@merck.com

Abstract

GARDASIL (Merck, Whitehouse Station, NJ) is a non-infectious recombinant, quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid proteins of human papillomavirus (HPV) types 6, 11, 16, and 18. GARDASIL is the first vaccine approved for use in women aged 9-26 years for the prevention of cervical cancer and genital warts, as well as vulvar and vaginal precancerous lesions. This report describes some of the key preclinical efforts, achievements in pharmaceutical development, in vivo animal evaluation, and clinical trial data.

PMID:
17259949
DOI:
10.1038/sj.clpt.6100055
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center